Health care stocks were declining premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.4% and the iShares Biotechnology ETF (IBB) was 0.2% lower recently.
Novo Nordisk (NVO) shares rose past 11% after the company said its phase 1b/2a clinical trial of amycretin in people with overweight or obesity showed positive results.
Allurion Technologies (ALUR) shares surged by more than 364% after the company said it plans to initiate a clinical study to investigate the combination of the Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.
Moderna (MRNA) shares were up over 1% after the company said it has been awarded a tender to supply its Covid-19 vaccine in the European Union, Norway and North Macedonia.